Results

1–3 of 3 results for intraocular inflammation

Efficacy and Durability of Brolucizumab in Patients Being Transitioned From Prior Anti-VEGF Therapy
Scott D Walter, MD, MSc, FASRS
Annual Meeting Talks
2021
Assessing Characteristics of Patients With or Without Intraocular Inflammation (IOI) In the Brolucizumab Treatment Arms From the HAWK and HARRIER, Phase 3 Studies
Jeffrey S. Heier, MD
Updates from the Field
2020
Aflibercept-Related Sterile Intraocular Inflammation
Philip J. Ferrone, MD, FASRS
Updates from the Field
2018